



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

June 1, 2020

DEPARTMENT MEMORANDUM

No. 2020 - 0265

TO : **DIRECTORS OF CENTERS FOR HEALTH DEVELOPMENT (CHDs), CHIEFS OF MEDICAL CENTERS, HOSPITALS, SANITARIA, EXECUTIVE DIRECTORS OF SPECIALTY HOSPITALS, MINISTER OF HEALTH – BANGSAMORO AUTONOMOUS REGION IN MUSLIM MINDANAO (MOH-BARMM), LOCAL GOVERNMENT UNITS (LGU) HEALTH FACILITIES AND OTHER CONCERNED**

SUBJECT : **PRICE ADJUSTMENT OF THE 2019 EDITION OF THE DRUG PRICE REFERENCE INDEX (DPRI)**

In relation to the newly signed Executive Order (EO) No. 104 entitled “*Improving Access to Healthcare through the Regulation of Prices in the Retail of Drugs and Medicine.*” wherein 87 drugs molecules (equivalent to 133 preparation/formulas) were placed under the Maximum Retail Price (MRP) and Maximum Wholesale Price (MWP). With this regard the following medicines are hereby adjusted based on the approved MWP:

Drug name	2019 DPRI	MWP (VAT exclusive)	Adjusted 2019 DPRI (VAT inclusive)
Rituximab 10 mg/mL, 50 mL vial	82,127.48	47,673.39	53,394.20
Trastuzumab 150 mg Lyophilized Powder	38,272.00	26,025.24	29,148.27
Sirolimus 1 mg tablet	275.00	185.72	208.01
Morphine 10 mg MR tablet	20.00	10.08	11.29
Morphine 30 mg MR tablet	71.79	26.18	29.32
Oxycodone + Naloxone 5 mg + 2.5 mg Prolonged Release	113.94	80.10	89.71
Oxycodone 10 mg tablet	127.16	115.69	129.75
Tinzaparin 10,000 anti-XA IU, 2 mL vial	1,414.62	711.57	796.96
Isosorbide Dinitrate 1 mg/mL, 10 mL ampule	485.72	131.78	147.59
Deferoxamine 500 mg vial	400.00	163.68	183.32
Sevelamer Carbonate 800 mg tablet	65.63	34.63	38.79
Beractant 25 mg/mL, 8 mL vial	17,811.36	14,086.19	15,776.53

Further, Department Memorandum No. 2019 - 0388 dated October 4, 2019 with the subject “*Availability of the 2019 Drug Price Reference Index (DPRI) Electronic or Soft Copy*” shall no longer be applicable for the aforementioned medicines. Lastly, this adjustment, specific for these medicines only, shall be applied for both **existing contracts** and succeeding procurements. Therefore, existing contracts with the awarded or procurement prices exceeding the adjusted 2019 DPRI shall be terminated pursuant to existing rules and regulations.

All CHDs and MOH-BARMM are hereby directed to disseminate the information to all Provincial Hospitals, Municipal Hospitals, City Hospitals, and Local Government Units and extend necessary assistance therefor.

For strict and prompt compliance.


MARIA ROSARIO SINGH-VERGEIRE MD, MPH, CESO IV
OIC – Undersecretary of Health
Health Regulation Team